Why the lab exists, and where it is going.
Our Vision
A future in which evidence-based psychedelic medicine is part of mainstream psychiatry, in which every clinician who needs these tools has been trained to use them, and in which the millions of people living without adequate options finally have some.
Our Mission
To enact impact through research: conducting rigorous clinical trials of psychedelic and consciousness-altering therapeutics across conditions, capturing what we learn, and training the next generation of clinicians so that knowledge moves from the study into practice.
Our Motto
“We move as a group and grow as individuals.” ENACT is a collective — researchers, clinicians, coordinators, and trainees moving together toward a shared purpose. When one of us publishes, we all publish. When one of us learns, we all learn.
The operational foundation of YPPS.
Beyond our direct research initiatives, ENACT provides the structural support, methodological frameworks, and collaborative environment that enable the incubation of specialized research divisions — transforming isolated expertise into interconnected knowledge networks that collectively advance the field.
Direct research
Clinical trials from first-in-population studies to Phase 3 registration trials, conducted under FDA oversight — with the whole person, not a single diagnosis, at the center.
Structural support
Methodological frameworks and a collaborative environment in which specialized research divisions incubate, mature, and stand on their own.
Knowledge in motion
Sustaining the continuous flow between inquiry and application, so that knowledge flows into practice and principles come alive through purpose.
Four lenses, and a flywheel.
Our research is organized around four lenses. Each one is a different kind of question to ask of the same study, and equity and ethics run across all four.
Research produces knowledge, knowledge trains clinicians, and what those clinicians carry into practice shapes the next research question. It is a loop, which is why the lab calls it a flywheel rather than a straight line.
- Research
- Knowledge
- Training
- Dissemination
- Outcomes & durability
- Context & integration
- Mechanisms & predictors
- Access & systems
Across all fourEquity & Ethics
Measures of relationship with suffering
A symptom score is not the only way to tell whether something has changed for a person. Our studies also measure:
- psychological flexibility
- meaning-making
- self-compassion
- social connectedness
- functional capacity
… plus symptoms.
Flagship ideaTransdiagnostic work with real-world patients, comorbidity allowed, non-directive support, and later group-format access.
The people behind the science.
The investigators and coordinators who run ENACT’s studies have a page of their own.
Meet the teamThe ecosystem around the lab.
Yale Program for Psychedelic Science
Our primary institutional partner, providing world-class research infrastructure and expertise.
Heffter Research Institute
Collaborative research initiatives spanning psychiatry, neuroscience, and clinical psychology.
U.S. Food & Drug Administration
All ENACT trials are conducted under FDA IND regulatory oversight.
Connecticut DMHAS
The Department of Mental Health and Addiction Services funds our transdiagnostic psilocybin study.
Steven & Alexandra Cohen Foundation
Philanthropic funding for our repeated-dosing psilocybin research in OCD.
Usona Institute
Sponsor of multicenter Phase 3 research into psilocybin for major depressive disorder. Studies ENACT is recruiting for are listed on Research & Trials.
Johns Hopkins University
Peer research center in the national psychedelic science network.
New York University
Collaborating academic site in multicenter psychedelic research.